Transdermal estradiol (tE2) as an alternative androgen deprivation therapy (ADT) in locally advanced prostate cancer
Ame Stephanie Ayemere, Jeanny B. Aragon-Ching · 2026
Read Transdermal estradiol (tE2) as an alternative androgen deprivation therapy (ADT) in locally advanced prostate cancer by Ame Stephanie Ayemere, Jeanny B. Aragon-Ching (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13462321.txt.
Description
Ame Stephanie Ayemere and Jeanny B Aragon-Ching discuss, in a 2026 commentary, estradiol skin patches as an alternative way to lower testosterone in advanced prostate cancer. Standard hormone treatment uses injections crushing both testosterone and estrogen, bringing bone loss, fractures, hot flashes, and muscle wasting. An older oral estrogen worked, yet raised clot risks by passing through the liver. Patches bypass the liver, keeping estrogen's benefits without that risk.
The commentary covers a randomized trial in 1,360 men treated between 2007 and 2022, which compared patches against injections. The question was whether patches controlled cancer as well, measured by time free of spread or death. Cancer control proved no worse with patches. Side effects differed: fewer problems tied to estrogen loss, yet more breast growth in men and more patch-related skin trouble. The authors present patches as an option whose trade-offs suit some patients better than others.
Catalog record
| CREATOR | Ame Stephanie Ayemere, Jeanny B. Aragon-Ching |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 12 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |